MannKind Corp (MNKD) SEC filings

MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30273% above fair value

$4.13−0.03 (-0.72%)

Close on Nov 13, 2026Market cap $1.33BP/E –Yield –

SEC filings

40 of MannKind's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Aug 21, 2026	Aug 21, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jul 23, 2026	Jul 24, 2026	SEC EDGAR
Current report	8-K	May 29, 2026	Jun 2, 2026	SEC EDGAR
Current report	8-K	May 27, 2026	May 28, 2026	SEC EDGAR
Current report	8-K	May 20, 2026	May 22, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 6, 2026	SEC EDGAR
Current report	8-K	May 6, 2026	May 6, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 7, 2026	Apr 7, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 26, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Current report	8-K	Nov 8, 2025	Nov 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Oct 7, 2025	Oct 9, 2025	SEC EDGAR
Current report	8-K	Aug 24, 2025	Aug 27, 2025	SEC EDGAR
Current report	8-K	Aug 24, 2025	Aug 25, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Aug 6, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 19, 2025	SEC EDGAR
Current report	8-K	May 9, 2025	May 15, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 14, 2025	Apr 1, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 26, 2025	SEC EDGAR
Current report	8-K	Feb 26, 2025	Feb 26, 2025	SEC EDGAR
Current report	8-K	Jan 2, 2025	Jan 6, 2025	SEC EDGAR
Current report	8-K	Dec 17, 2024	Dec 18, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Aug 13, 2024	Aug 14, 2024	SEC EDGAR
Current report	8-K	Aug 7, 2024	Aug 7, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 7, 2024	SEC EDGAR
Current report	8-K	May 15, 2024	May 16, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR
Proxy statement	DEF 14A	May 15, 2024	Apr 5, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in MannKind's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Mar 3, 2017
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MNKD.

Compare: MNKD vs LQDA · MNKD vs XERS · MNKD vs IRWD · MNKD vs AMPH · MNKD vs OPK

Revenue growth31.7% · median 18.1%

Gross margin88.6% · median 56.6%

Operating margin-2.9% · median 12.7%

Net margin-18.1% · median -1.8%

Company	Revenue	Growth
AMPH	$745.79M	+3.1%
LQDA	$621.87M	+798.4%
OPK	$501.64M	-8.3%
MNKD	$413.37M	+31.7%
IRWD	$400.30M	+18.1%
XERS	$368.26M	+38.4%

Company

Next earnings (est.): Feb 25, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 241
Held by institutions: 56.7%
Auditor: Deloitte & Touche LLP
SEC CIK: 899460

Advertisement
300 × 250

See a number that looks wrong?